The role of captopril in titanium alloy particle-induced inflammatory osteolysis was investigated. BALB/c mice (n = 32) were divided into four groups, an untreated control group and three treatment groups given 12.5, 25 or 50 mg/kg per day captopril. Intraperitoneal injections of either 0.9% saline (control) or captopril began 2 days before the introduction of titanium alloy particles and calvaria bone from a syngeneic mouse into established air pouches. Mice were sacrificed 10 days after bone/titanium alloy implantation, and pouch membranes and implants were collected for histological and molecular analysis. Low-dose captopril (12.5 mg/kg per day) was found to inhibit titanium particleinduced tissue inflammation and inflammatory osteolysis. Pouch membrane thickness and inflammatory cellular infiltration were significantly reduced relative to controls. Captopril also inhibited production of the inflammatory cytokines tumour necrosis factor-a, interleukin-1b and receptor activator of nuclear factor-kB ligand compared with controls. This study provides evidence that a low-dose of captopril can inhibit titanium particleinduced inflammatory osteolysis.
Introduction
Wear debris-induced osteolysis and aseptic loosening is the most common complication of total joint replacement surgery. 1 In the 10 years after joint replacement, up to 20% of patients will have radiographic loosening of the joint. 2, 3 The pathogenesis of aseptic loosening is not fully understood, but an inflammatory reaction is widely considered to be the major cause of osteolysis finally resulting in aseptic loosening. 4 − 7 Gene therapy to counteract this process has been investigated and has been found effectively to inhibit osteolysis caused by wear debris. Current concerns about the biosafety of gene therapy will, however, limit its clinical use for the foreseeable future. 8 − 10 In the meantime, investigation of pharmacological interventions may improve inflammatory osteolysis associated with aseptic loosening.
Captopril, an oral active inhibitor of angiotensin-converting enzyme (ACE), is a safe and effective agent for the management of hypertension and heart failure. 11 Several published animal studies have indicated that captopril has anti-inflammatory activities. 12, 13 The action of captopril is probably mediated through the inhibition of W Zhang, H Zhao, X Peng et al.
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proinflammatory cytokine production. 12 The aim of the present study was to investigate whether captopril might inhibit the inflammatory reactions occurring during osteolysis induced by wear debris. A murine air pouch with cranial bone implantation model was used to investigate the effects of different doses of captopril in titanium alloy particle-induced inflammatory osteolysis in vivo.
Materials and methods

PARTICLE PREPARATION
Titanium alloy particles (diameters 0.1 -20 µm) were obtained from Alfa Aesar (Ward Hill, MA, USA). The particles were sterilized, then washed three times in sterile 10 mM phosphate buffered saline (PBS), pH 7.4, suspended in sterile 10 mM PBS at a concentration of 15 mg/ml, and stored at 4°C until needed.
MOUSE OSTEOLYSIS MODEL AND CAPTOPRIL TREATMENT
The Institutional Animal Care and Use Committee of Shanghai Jiaotong University approved all animal procedures.
Female BALB/c mice, aged 10 weeks were purchased from the Shanghai Laboratory Animal Centre (Shanghai, China). The mice were randomly assigned to four experimental groups, with eight in each group: group 1 (control group), without captopril treatment (0.5 ml 0.9% saline); group 2, 12.5 mg/kg per day captopril; group 3, 25 mg/kg per day captopril; and group 4, 50 mg/kg per day captopril. The dorsal area of each mouse (2 × 2 cm) was cleaned and shaved and 2 ml of sterile air was injected subcutaneously to establish an air pouch. To maintain the pouch, 0.5 ml of sterile air was injected into the pouch each day for 6 days. After 6 days, mice with established air pouches were anaesthetized by intraperitoneal injection of pentobarbital (50 mg/kg). A 0.5-cm incision overlying the pouch was made and a section of calvaria bone (approximately 0.8 × 0.6 cm) from a genetically identical donor mouse was inserted into the pouch, along with 0.3 ml of titanium alloy particle suspension to provoke an inflammatory response. The pouch layers and the skin incision were then closed using 4-0 prolene sutures.
At 2 days before the bone insertion, captopril (dose according to group assignment) dissolved in 0.9% saline, or control (0.9% saline), was injected intraperitoneally. Injections continued daily until sacrifice of the mice 10 days after bone/titanium alloy implantation. The pouch membranes containing the implanted bone were harvested for histological evaluation and molecular analysis.
HISTOLOGICAL EVALUATION AND IMAGE ANALYSIS
Tissue samples were fixed in 4% polyoxymethylene (pH 7.4) for 24 h and, after decalcification in 10% ethylenediamine tetraacetic acid, the specimens were processed for paraffin embedding. Tissue sections (6 µm) were stained with haematoxylin and eosin to evaluate pouch membrane inflammation and implant bone erosion. The stained sections were examined under a light microscope (Olympus DP70; Olympus Optical Co., Tokyo, Japan), and digital photomicrographs were captured and analysed using a computerized image analysis system with Image-Pro ® Plus software, version 5.0 (Media Cybernetics, Inc., Bethesda, MD, USA). The pouch membrane thickness and the total numbers of infiltrated cells were measured using digital image analysis. Four separate sections per specimen were analysed in a W Zhang, H Zhao, X Peng et al. Captopril and inflammatory osteolysis blinded fashion. Pouch membrane thickness was measured at six points on each section and six random 100-µm longitudinal pouch areas were selected to count total cells (cells/mm 2 ), based upon nucleus count.
GENE EXPRESSION OF INFLAMMATORY CYTOKINES
Total RNA was extracted from pouch tissue using TRIzol ® reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions, and cDNA was synthesized from the total RNA using the SYBR ® PrimeScript TM reverse transcriptionpolymerase chain reaction (RT-PCR) kit (Takara Bio Inc., Shiga, Japan). Quantitative real-time RT-PCR was performed to quantify the relative levels of mRNA for tumour necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and receptor activator of nuclear factor-κB ligand (RANKL), using the SYBR ® PrimeScript TM RT-PCR kit and an ABI7500 real-time thermal cycler (Applied Biosystems, Carlsbad, CA, USA) according to the manufacturer's instructions. Genespecific primers for TNF-α, IL-1β and RANKL were designed using Primer 5.0 software (Premier Biosoft International, Palo Alto, CA, USA) ( Table 1 ). The housekeeping gene, βactin, was amplified as an internal control. The cycling programme involved preliminary denaturation at 95°C for 2 min, followed by 40 cycles of denaturation at 95°C for 15 s and annealing at 60°C for 1 min.
To determine the relative level of gene expression following PCR amplification, the comparative threshold cycle (C T ) method with arithmetic formulae was used. Subtracting the C T of the housekeeping gene from the C T of the target gene yielded the ∆C T for each group (control and experimental groups), which was entered into the equation 2 -∆CT .
STATISTICAL ANALYSIS
The mean ± SD of the data were calculated. Statistical analyses were carried out using the SPSS ® statistical package, version 11.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . Statistical analysis among groups was performed by analysis of variance. A P-value of < 0.05 was considered to be statistically significant.
Results
Histological analysis of the pouch tissue showed that pouches injected with titanium particles developed inflammatory changes ( Fig. 1A) . Captopril treatment ameliorated the inflammation within the pouch (Fig. 1B  -1D ).
TABLE 1: Gene-specific primers for tumour necrosis factor-a (TNF-a), interleukin-1b (IL-1b) and receptor activator of nuclear factor-kB ligand (RANKL), and the housekeeping gene b-actin
Gene Primers
TNF-α Forward: 5'-GAGTCCGGGCAGGTCTACTTT-3' Reverse: 5'-CAGGTCACTGTCCCAGCATCT-3'
IL-1β
Forward: 5'-ACCTGGGCTGTCCTGATGAGAG-3' Reverse: 5'-CCACGGGAAAGACACAGGTAGC-3' RANKL Forward: 5'-TGTACTTTCGAGCGCAGATG-3' Reverse: 5'-CCCACAATGTGTTGCAGTTC-3' β-Actin Forward: 5'-CCTCTATGCCAACACAGTGC-3' Reverse: 5'-GTACTCCTGCTTGCTGATCC-3'
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Air pouch membrane thickness and total cell number were measured to evaluate particle-induced inflammation. 14 Captopril significantly decreased titanium particleinduced membrane thickness compared with the control (P < 0.05), but there were no significant differences between membrane thicknesses for the different concentrations of captopril; increasing the dose of captopril did not further reduce membrane thickness ( Fig. 2A) .
Cellular infiltration in titaniumstimulated pouches was also significantly decreased after captopril treatment compared with control (P < 0.05; Fig. 2B ). There were no significant differences in cell numbers with increasing dose of captopril, indicating no further reduction in the degree of cellular infiltration.
Captopril significantly decreased the Fig. 3 ). There were no significant differences of levels of TNF-α, IL-1β and RANKL mRNA between the different doses of captopril, showing that the expression of these proinflammatory factor genes was not affected by dose.
The administration of captopril at all doses was well tolerated by the animals and there were no observable detrimental side effects. All animals had regular food intake and their body weight remained constant.
FIGURE 2:
Histological assessment of (A) pouch membrane thickness and (B) total cell counts from mice implanted with syngeneic calvaria bone and titanium alloy particles in the untreated control group (0.9% saline injections) and in those receiving intraperitoneal injections of 12.5, 25 or 50 mg/kg per day captopril for 2 days before bone and particle implantation and until sacrifice 10 days following implantation (mean ± SD for eight mice per group; *P < 0.05 versus control) 
Discussion
Total joint replacement is a successful operating procedure widely used to reduce pain and improve joint function, however, aseptic loosening, the most common complication of joint replacement, still affects a large proportion of postoperative patients. 2 Wear debris-induced persistent inflammation and osteoclastogenesis are two critical factors in the aetiology of aseptic loosening. 15, 16 Wear debris can stimulate macrophages to generate proinflammatory factors, such as TNF-α, IL-1β and RANKL. 17, 18 These factors can promote osteoclastogenesis and, eventually, aggravate the absorption of periprosthetic osteolysis. 19 At present, some progress on the use of drugs or gene therapy to inhibit wear debris-induced inflammatory osteolysis has been made, but advances are still far from clinical application. 20 To mimic the environment of a replaced joint, a murine air pouch with a cranial bone implantation model was constructed. This model was designed to be simple and reliable; its advantages are the ability to reflect the soft tissue response to wear debris and the ease with which inflammatory cytokines can be analysed.
Titanium particles were used to provoke an inflammatory response and injected captopril was found to alleviate inflammatory osteolysis in the titaniumstimulated tissue, even at the lowest dose of 12.5 mg/kg per day. Captopril reduced pouch membrane thickness, inflammatory cellular infiltration and bone resorption. A decline in TNF-α, IL-1β and RANKL mRNA levels with captopril was demonstrated. TNFα and IL-1β are the major cytokines detected in periprosthetic tissue and are known to be potent mediators of bone resorption associated with aseptic loosening. 21, 22 Thus, the inhibitory effects of captopril on inflammatory cytokine production may represent a therapeutic strategy to reduce inflammation provoked by wear debris. The inhibitory effect of captopril on RANKL production also suggested indirect inhibition of osteoclastogenesis, as RANK/RANKL signalling plays a critical role in inflammatory osteoclastogenesis associated with aseptic loosening. 23 Captopril was well tolerated by the mice at all doses in the present study and there were no observable detrimental side-effects. All the mice had regular food intake and their body weight remained constant.
In conclusion, captopril, at a low concentration (12.5 mg/kg per day), inhibited wear debris-induced inflammatory osteolysis and represents a promising drug candidate for the treatment and prevention of aseptic loosening because of its proven clinical safety (and efficacy) for the treatment of hypertension and heart failure. This evidence of the strong inhibitory effect of captopril on inflammatory osteolysis is of potential clinical importance.
